advanced cancer pain
Conditions
Interventions
Experimental Group:oral administration of Bulleyaconitin A+IDDS
Placebo Group:Placebo+IDDS
Sponsors
The First Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. With diagnosis of terminal cancer carcinoma by histology or cytology; 2. Control the pain score to VAS = 18 years; 4. Expected survival >= 3 months; 5. Informed consent form signed.
Exclusion criteria
Exclusion criteria: 1. Bulleyaconitin A allergy; 2. Brain tumor and leukemia; 3. Pregnant and lactating women; 4. Concurrent radiotherapy was performed, and first-line chemotherapy was randomly assigned 7 days before; 5. Complications requiring surgical intervention; 6. Patients with postherpetic pain, trigeminal neuralgia, and diabetic neuralgia; 7. Organ transplant recipients; 8. With history of severe organ diseases, such as heart, lung, liver; 9. Active clinical severe infection; 10. Opioid abusers; 11. Schizophrenia or psychiatric substance abuse; 12. Unable to take oral medicine; 13. Participating in clinical trials of other analgesics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Growth rate of morphine consumption; | — |
Secondary
| Measure | Time frame |
|---|---|
| Average VAS score over 28 days;Drug toxicity evaluation;Constipation score of PAC-SYM;Pruritus score of WI-NRS;Sedation scores of RASS;Quality of life (QLQ-C30, V3.0); | — |
Countries
China
Contacts
Public ContactXia Feng
The First Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed